Insmed announced a Phase 3 win showing that adding Arikayce to standard therapy improved respiratory symptoms and culture conversion in patients with newly diagnosed Mycobacterium avium complex (MAC) lung infection. The trial met its objectives for patients who had not previously received antibiotics for MAC, supporting expanded use beyond the drug’s accelerated approval indication. Company commentary and STAT coverage indicate Insmed plans to pursue label expansion into earlier disease, which could materially increase the drug’s commercial opportunity and position Arikayce as a second blockbuster for the company if regulators accept the data. Arikayce previously received accelerated approval for more advanced, treatment‑refractory MAC.